Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer?

Journal of Urology

Volumn 159, Issue 1, 1998, Pages 265-269

  Pycha, Armin ^a   Mian, Christine ^a   Hofbauer, Johann ^a   Haitel, Andrea ^a   Wiener, Helene ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

BCG therapy; Bladder cancer; Chromosomal aberrations; FISH; Intravesical chemotherapy

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DRUG INSTILLATION; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGIONAL PERFUSION;

EID: 0031986367     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64079-5     Document Type: Article

References (19)

1. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol., 27 (Suppl. 1): 2, 1995.
2. Ratliff, T. L., Ritchey, J. K., Yuan, J. J. J., Andriole, G. L. and Catalona, W. J.: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150: 1018, 1993.
3. Soloway, M. S.: Managing superficial bladder cancer: an overview. Urol. (Suppl.), 40: 5, 1992.
4. Vegt, P. D. J., Witjes, J. A., Witjes, W. P. J., Doesburg, W. H., Debruyne, F. M. J. and van der Meijden, A. P. M.: A randomized study of intravesical mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol., 153: 929, 1995.
5. Nadler, R. B., Catalona, W. J., Hudson, M. A. and Ratliff, T. L.: Durability of the tumor-free response for intravesical Bacillus Calmette-Guerin therapy. J. Urol., 152: 367, 1994.
6. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
7. Spruck, C. H., III, Ohneseit, P. F., Gonzales-Zulueta, M., Esrig, D., Miyao, N., Tsai Lerner, S. P., Schmutte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G. and Jones, P. A.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
8. Waldman, F. M., Caroll, P. R., Kerschmann, R., Cohen, M. B., Field, F. G. and Mayall, B. H.: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res., 51: 3807, 1991.
9. Olumni, A. F., Tsai, Y. C., Nichols, P. W., Skinner, D. G., Cain, D. R., Bender, L. I. and Jones, P. A.: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081, 1990.
10. Pycha, A., Mian, C., Haitel, A., Hofbauer, J., Wiener, H. and Marberger, M.: Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (pTa) bladder cancer. J. Urol., 157: 2116, 1997.
11. Sandberg, A. A. and Berger, C. S.: Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J. Urol., 151: 545, 1994.
12. Simak, R., Wiener, H., Foeger, A., Susani, M., Zhang, Z. F., Maier, U. and Marberger, M.: Cytomorphometry in the monitoring of bladder cancer under intravesical chemotherapy. Eur. Urol., 29: 391, 1996.
13. Hermanek, P. and Sobin, L. H.: UICC TNM Classification of Malignant Tumours. Berlin, Heidelberg, New York, London, Paris, Tokyo, Honkong, Barcelona, Budapest. Fourth Edition, 2nd revision, 1992.
14. Pinkel, D., Straume, T. and Gray, J. W.: Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc. Natl. Acad. Sci., 83: 2934, 1986.
15. Flamm, J. and Steiner, R.: Stellenwert der differenzierten transurethralen Resektion beim primären oberflächlichen Blasenkarzinom. Urologe A, 30: 111, 1991.
16. Ratliff, T. L.: Role of the immune response in BCG for bladder cancer. Eur. Urol., 21 (suppl. 2): 17, 1992.
17. Murphy, W. M., Soloway, M. S. and Crabtree, W. N.: The morphologic effects of mitomycin in mammalian urinary bladder. Cancer, 47: 2567, 1981.
18. Akaza, H.: BCG treatment of existing Ta, T1 tumours or carcinoma in situ of the bladder. Eur. Urol., 27 (suppl. 1): 9, 1995.
19. Van der Meijden, A. P. M.: Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur. Urol., 27 (suppl. 1): 23, 1995.